NuGene International Valuation
| NUGN Stock | USD 0 0 20.00% |
NuGene International seems to be fairly valued based on Macroaxis valuation methodology. Our model forecasts the value of NuGene International from analyzing the firm fundamentals such as return on asset of -9.44, and Operating Margin of (0.11) % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that NuGene International's price fluctuation is out of control at this time. Calculation of the real value of NuGene International is based on 3 months time horizon. Increasing NuGene International's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since NuGene International is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NuGene Pink Sheet. However, NuGene International's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.004 | Real 0.00384 | Hype 0.004269 |
The intrinsic value of NuGene International's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NuGene International's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NuGene International helps investors to forecast how NuGene pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NuGene International more accurately as focusing exclusively on NuGene International's fundamentals will not take into account other important factors: NuGene International Total Value Analysis
NuGene International is now forecasted to have valuation of 14.83 M with market capitalization of 11.61 M, debt of 2.8 M, and cash on hands of 118.34 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the NuGene International fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
14.83 M | 11.61 M | 2.8 M | 118.34 K |
NuGene International Investor Information
The company recorded a loss per share of 0.29. NuGene International had not issued any dividends in recent years. The entity had 376:25 split on the 27th of January 2015. Based on the analysis of NuGene International's profitability, liquidity, and operating efficiency, NuGene International is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.NuGene International Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NuGene International has an asset utilization ratio of 252.05 percent. This suggests that the Company is making $2.52 for each dollar of assets. An increasing asset utilization means that NuGene International is more efficient with each dollar of assets it utilizes for everyday operations.NuGene International Ownership Allocation
NuGene International maintains a total of 219 Million outstanding shares. NuGene International secures 5.85 % of its outstanding shares held by insiders and 0.0 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.NuGene International Profitability Analysis
The company reported the previous year's revenue of 1.47 M. Net Loss for the year was (75.19 K) with loss before overhead, payroll, taxes, and interest of (209.4 K).About NuGene International Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of NuGene International. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of NuGene International based exclusively on its fundamental and basic technical indicators. By analyzing NuGene International's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of NuGene International's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of NuGene International. We calculate exposure to NuGene International's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NuGene International's related companies.Livento Group, Inc. engages in the film and television production activities. Livento Group, Inc. was incorporated in 2013 and is based in New York, New York. Nugene International operates under Shell Companies classification in the United States and is traded on OTC Exchange. It employs 11 people.
8 Steps to conduct NuGene International's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates NuGene International's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct NuGene International's valuation analysis, follow these 8 steps:- Gather financial information: Obtain NuGene International's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine NuGene International's revenue streams: Identify NuGene International's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research NuGene International's industry and market trends, including the size of the market, growth rate, and competition.
- Establish NuGene International's growth potential: Evaluate NuGene International's management, business model, and growth potential.
- Determine NuGene International's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate NuGene International's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
NuGene International Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Retained Earnings | -12.7 M | |
| Quarterly Revenue Growth Y O Y | -0.818 |
Other Information on Investing in NuGene Pink Sheet
NuGene International financial ratios help investors to determine whether NuGene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NuGene with respect to the benefits of owning NuGene International security.